Protagonist Therapeutics/$PTGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Protagonist Therapeutics
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Ticker
$PTGX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
124
ISIN
US74366E1029
Website
PTGX Metrics
BasicAdvanced
$3.3B
61.24
$0.86
2.64
-
Price and volume
Market cap
$3.3B
Beta
2.64
52-week high
$60.60
52-week low
$32.50
Average daily volume
963K
Financial strength
Current ratio
17.255
Quick ratio
17.129
Long term debt to equity
1.421
Total debt to equity
1.649
Profitability
EBITDA (TTM)
28.053
Gross margin (TTM)
100.00%
Net profit margin (TTM)
27.04%
Operating margin (TTM)
13.10%
Effective tax rate (TTM)
1.57%
Revenue per employee (TTM)
$1,680,000
Management effectiveness
Return on assets (TTM)
2.48%
Return on equity (TTM)
8.99%
Valuation
Price to earnings (TTM)
61.245
Price to revenue (TTM)
15.785
Price to book
4.75
Price to tangible book (TTM)
4.75
Price to free cash flow (TTM)
9.783
Free cash flow yield (TTM)
10.22%
Free cash flow per share (TTM)
539.97%
Growth
Revenue change (TTM)
-34.02%
Earnings per share change (TTM)
-68.10%
3-year revenue growth (CAGR)
64.26%
3-year earnings per share growth (CAGR)
-30.61%
What the Analysts think about PTGX
Analyst ratings (Buy, Hold, Sell) for Protagonist Therapeutics stock.
Bulls say / Bears say
Protagonist Therapeutics' drug candidate, icotrokinra, demonstrated superiority over placebo and the approved oral TYK2 inhibitor Sotyktu in the ICONIC ADVANCE 1 and 2 trials, leading to a $165 million milestone payment from Janssen. (Investing.com)
Analysts from firms such as H.C. Wainwright, TD Cowen, and Truist Securities have maintained Buy ratings for Protagonist Therapeutics, reflecting confidence in the company's commercial prospects. (Investing.com)
Protagonist Therapeutics has been named to Fast Company's World's Most Innovative Companies for 2025, securing a position among the top 5 Most Innovative Biotechnology companies, highlighting their pioneering work in peptide-based drug development. (StockTitan)
Protagonist Therapeutics' CEO sold $4.68 million in stock, which could be perceived as a lack of confidence in the company's future performance. (Investing.com)
The company's Chief Medical Officer sold $1.41 million in stock, potentially signaling concerns about the company's valuation or future prospects. (Investing.com)
Wall Street Zen downgraded Protagonist Therapeutics to a 'Sell' rating, indicating potential concerns about the company's future performance. (MarketBeat)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
PTGX Financial Performance
Revenues and expenses
PTGX Earnings Performance
Company profitability
PTGX News
AllArticlesVideos
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
Accesswire·2 weeks ago
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
Business Wire·1 month ago
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Protagonist Therapeutics stock?
Protagonist Therapeutics (PTGX) has a market cap of $3.3B as of July 11, 2025.
What is the P/E ratio for Protagonist Therapeutics stock?
The price to earnings (P/E) ratio for Protagonist Therapeutics (PTGX) stock is 61.24 as of July 11, 2025.
Does Protagonist Therapeutics stock pay dividends?
No, Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Protagonist Therapeutics dividend payment date?
Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Protagonist Therapeutics?
Protagonist Therapeutics (PTGX) has a beta rating of 2.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.